Recurrent Non-small Cell Lung Cancer Terminated Phase 2 Trials for Erlotinib (DB00530)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00976677Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerTreatment